Lisa Astor | Authors

January 21, 2023

NRG-GI002 helps to provide further total neoadjuvant therapy outcome data from multi-institutional national clinical trials that can benchmark and be used for future locally advanced rectal cancer outcomes, according to Thomas J. George, MD, FACP.

January 17, 2023

Several studies with data released or presented in 2022 did not meet the threshold for significance or achieve their primary end points. Although such results are disappointing, takeaways from the trials can be used by the field as a whole to improve clinical trial design and achieve greater success in the future.

December 28, 2022

The generation in development offers reasons for excitement about improved outcomes for patients with breast cancer.

December 27, 2022

New clinical trial data have shown that patients with IHC 1+ or IHC 2+/ISH– disease, but no ERBB2 amplification, could still benefit from HER2 targeted therapies.

December 25, 2022

Neoadjuvant immunotherapy has begun to show benefit for the treatment of patients with rectal cancer as well as for those with colorectal cancer.

December 09, 2022

Improvement in progression-free and overall survival was shown with sacituzumab govitecan in the phase 3 TROPiCS-02 trial.